Mustafa Güney
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mustafa Güney has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Ayfer Bakır
Department of Medical Microbiology, Ankara Etlik City Hospital, Ankara 06170, Türkiye
5 shared publications - Batuhan Erdoğdu
Department of Hematology, Gülhane Training and Research Hospital, Ankara 06010, Türkiye
3 shared publications - Emine Koç
Department of Analytical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara 06230, Türkiye
3 shared publications - Murat Yıldırım
Department of Hematology, Gülhane Training and Research Hospital, Ankara 06010, Türkiye
3 shared publications - Mustafa Çelebier
Department of Analytical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara 06230, Türkiye
3 shared publications - Ozan Kaplan
Department of Analytical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara 06230, Türkiye
3 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by MDPI AG in Metabolites
- Vol. 16 (11) , 809
Plasma Metabolomic Profiling in Essential Thrombocythemia: Pathway-Level Alterations and Their Relationship to Treatment Status, Platelet Count, and JAK2V617F Status
Background/Objectives: Essential thrombocythemia (ET) is a JAK-STAT-driven myeloproliferative neoplasm with an incompletely defined metabolic phenotype. This study aimed to characterize the plasma metabolome of ET and to determine whether it differs according to JAK2V617F status, platelet count (≥450 vs. 1.5 or 2Y = 0.96; nested cross-validation Q2 = 0.91; permutation p = 0.001). Nineteen metabolites met the criteria: seven Level 1 identifications (succinate, an aminobutyrate isomer, uridine and N-acetylphenylalanine higher; proline, glucuronolactone and quinaldate lower in ET) and twelve Level 3 candidates dominated by platelet-derived eicosanoids, including 11-dehydro-thromboxane B2 (detected in 26% of controls and 99% of patients) and thromboxane B2 (4% and 84%), prostaglandin D2/E2 and B1/A1 isomers, a hydroxy-docosahexaenoic acid isomer, and corticosteroid intermediates. Reactome over-representation analysis, which rests mainly on Level 3 candidates, ranked synthesis of prostaglandins and thromboxanes and arachidonate metabolism highest (FDR 7 × 10−5), followed by fatty acid metabolism, pyrimidine catabolism and, on the basis of Level 3 candidates only, mineralocorticoid biosynthesis. The signature was similar in direction across cytoreductive-therapy, platelet-count and JAK2V617F strata. Conclusions: These exploratory data describe a plasma metabolite signature of aspirin-treated ET dominated by platelet-derived eicosanoids, together with changes in succinate and pyrimidine-related metabolites and candidate changes in corticosteroid intermediates; because aspirin exposure and disease status were fully confounded, the signature requires confirmation with targeted methods in independent cohorts.
- 23 October 2026
- Published by MDPI AG in Metabolites
- Vol. 16 (11) , 809
Open AccessPlasma Metabolomic Profiling in Essential Thrombocythemia: Pathway-Level Alterations and Their Relationship to Treatment Status, Platelet Count, and JAK2V617F Status
Background/Objectives: Essential thrombocythemia (ET) is a JAK-STAT-driven myeloproliferative neoplasm with an incompletely defined metabolic phenotype. This study aimed to characterize the plasma metabolome of ET and to determine whether it differs according to JAK2V617F status, platelet count (≥450 vs. 1.5 or 2Y = 0.96; nested cross-validation Q2 = 0.91; permutation p = 0.001). Nineteen metabolites met the criteria: seven Level 1 identifications (succinate, an aminobutyrate isomer, uridine and N-acetylphenylalanine higher; proline, glucuronolactone and quinaldate lower in ET) and twelve Level 3 candidates dominated by platelet-derived eicosanoids, including 11-dehydro-thromboxane B2 (detected in 26% of controls and 99% of patients) and thromboxane B2 (4% and 84%), prostaglandin D2/E2 and B1/A1 isomers, a hydroxy-docosahexaenoic acid isomer, and corticosteroid intermediates. Reactome over-representation analysis, which rests mainly on Level 3 candidates, ranked synthesis of prostaglandins and thromboxanes and arachidonate metabolism highest (FDR 7 × 10−5), followed by fatty acid metabolism, pyrimidine catabolism and, on the basis of Level 3 candidates only, mineralocorticoid biosynthesis. The signature was similar in direction across cytoreductive-therapy, platelet-count and JAK2V617F strata. Conclusions: These exploratory data describe a plasma metabolite signature of aspirin-treated ET dominated by platelet-derived eicosanoids, together with changes in succinate and pyrimidine-related metabolites and candidate changes in corticosteroid intermediates; because aspirin exposure and disease status were fully confounded, the signature requires confirmation with targeted methods in independent cohorts.
- Open Access
- 1 October 2025
- Published by Modestum Ltd in Journal of Clinical and Experimental Investigations
- Vol. 16 (4) , em00847
The relationship between cytomegalovirus IgM index value and low IgG avidity
Background: Serological markers like anti-CMV IgG, IgM, and IgG avidity are used to diagnose cytomegalovirus (CMV) infection. This study assessed the seroprevalence of CMV antibodies and the predictive value of the CMV IgM index for low IgG avidity. Materials and methods: A total of 5,666 serum samples collected between January 2017 and June 2021 were analyzed for CMV IgG and IgM using chemiluminescence immunoassay. IgG avidity was tested by enzyme-linked immunosorbent assay in 40 IgG-positive and borderline/positive IgM samples. Results: Anti-CMV IgM seroprevalence was 4.3%. Low IgG avidity was detected in 2 of 40 cases (5.0%). Receiver operating characteristic (ROC) analysis identified 2.26 as the optimal IgM index cut-off, yielding 100% sensitivity, 86.8% specificity (area under the curve = 0.895, p = 0.06). Conclusions: High CMV IgM index values may indicate low IgG avidity but are not sufficient alone. Results should always be interpreted alongside avidity testing. Threshold use without confirmation is not recommended.
- 1 October 2025
- Published by Modestum Ltd in Journal of Clinical and Experimental Investigations
- Vol. 16 (4) , em00847
Open AccessThe relationship between cytomegalovirus IgM index value and low IgG avidity
Background: Serological markers like anti-CMV IgG, IgM, and IgG avidity are used to diagnose cytomegalovirus (CMV) infection. This study assessed the seroprevalence of CMV antibodies and the predictive value of the CMV IgM index for low IgG avidity. Materials and methods: A total of 5,666 serum samples collected between January 2017 and June 2021 were analyzed for CMV IgG and IgM using chemiluminescence immunoassay. IgG avidity was tested by enzyme-linked immunosorbent assay in 40 IgG-positive and borderline/positive IgM samples. Results: Anti-CMV IgM seroprevalence was 4.3%. Low IgG avidity was detected in 2 of 40 cases (5.0%). Receiver operating characteristic (ROC) analysis identified 2.26 as the optimal IgM index cut-off, yielding 100% sensitivity, 86.8% specificity (area under the curve = 0.895, p = 0.06). Conclusions: High CMV IgM index values may indicate low IgG avidity but are not sufficient alone. Results should always be interpreted alongside avidity testing. Threshold use without confirmation is not recommended.
- Open Access
- 22 September 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (9) , 630
Metabolomic Profiling Reveals Distinct Signatures in Primary and Secondary Polycythemia
Background/Objectives: The differential diagnosis between primary polycythemia vera (PV) and secondary polycythemia (SP) presents significant clinical challenges owing to substantial phenotypic overlap. This investigation utilized untargeted metabolomic approaches to elucidate disease-specific metabolic perturbations and evaluate the metabolic consequences of cytoreductive therapeutic interventions. Methods: Plasma specimens obtained from PV patients (n = 40) and SP patients (n = 25) underwent comprehensive metabolomic profiling utilizing liquid chromatography–mass spectrometry (LC-MS) platforms. Multivariate statistical analyses, including principal component analysis (PCA), were employed in conjunction with pathway enrichment analyses to characterize disease-associated metabolic dysregulation. Additionally, receiving treatment (tPV) (n = 25) and not receiving treatment (ntPV) (n = 15) PV patients were compared to assess therapeutic metabolic effects. Results: Comprehensive metabolomic analysis identified 67 significantly altered metabolites between PV and SP patients, with 36 upregulated and 31 downregulated in PV. Key upregulated metabolites in PV included thyrotropin-releasing hormone, 3-sulfinoalanine, nicotinic acid adenine dinucleotide, and protoporphyrin IX, while 4-hydroxyretinoic acid and deoxyuridine were notably downregulated. Pathway enrichment analysis revealed disruptions in taurine, glutamate, nicotinate, and cysteine metabolism in PV. ntPV patients exhibited higher glucose and octanoyl-CoA levels compared to treated patients, indicating the normalization of glucose and fatty acid metabolism with cytoreductive therapy. ntPV was also associated with altered B-vitamin metabolism, including decreased nicotinic acid adenine dinucleotide and increased nicotinamide ribotide levels. Cross-comparison analysis revealed overlapping pathway enrichment in glutamate metabolism, nicotinate and nicotinamide metabolism, and cysteine metabolism between both comparisons. Conclusions: This study demonstrates that PV and SP exhibit fundamentally distinct metabolic signatures, providing novel insights into disease pathogenesis and potential diagnostic biomarkers. The identification of oxidative stress signatures, disrupted energy metabolism, and altered B-vitamin cofactor pathways distinguishes PV from SP at the molecular level. Cytoreductive therapy significantly normalizes metabolic dysregulation, particularly glucose and nucleotide metabolism, validating current therapeutic approaches while revealing broader systemic treatment effects. The metabolic signatures identified, particularly the combination of deoxyuridine, thyrotropin-releasing hormone, and oxidative stress metabolites, may serve as complementary diagnostic tools to traditional morphological and molecular approaches. These findings advance our understanding of myeloproliferative neoplasm pathophysiology and provide a foundation for developing metabolically targeted therapeutic strategies and precision medicine approaches in PV management.
- 22 September 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (9) , 630
Open AccessMetabolomic Profiling Reveals Distinct Signatures in Primary and Secondary Polycythemia
Background/Objectives: The differential diagnosis between primary polycythemia vera (PV) and secondary polycythemia (SP) presents significant clinical challenges owing to substantial phenotypic overlap. This investigation utilized untargeted metabolomic approaches to elucidate disease-specific metabolic perturbations and evaluate the metabolic consequences of cytoreductive therapeutic interventions. Methods: Plasma specimens obtained from PV patients (n = 40) and SP patients (n = 25) underwent comprehensive metabolomic profiling utilizing liquid chromatography–mass spectrometry (LC-MS) platforms. Multivariate statistical analyses, including principal component analysis (PCA), were employed in conjunction with pathway enrichment analyses to characterize disease-associated metabolic dysregulation. Additionally, receiving treatment (tPV) (n = 25) and not receiving treatment (ntPV) (n = 15) PV patients were compared to assess therapeutic metabolic effects. Results: Comprehensive metabolomic analysis identified 67 significantly altered metabolites between PV and SP patients, with 36 upregulated and 31 downregulated in PV. Key upregulated metabolites in PV included thyrotropin-releasing hormone, 3-sulfinoalanine, nicotinic acid adenine dinucleotide, and protoporphyrin IX, while 4-hydroxyretinoic acid and deoxyuridine were notably downregulated. Pathway enrichment analysis revealed disruptions in taurine, glutamate, nicotinate, and cysteine metabolism in PV. ntPV patients exhibited higher glucose and octanoyl-CoA levels compared to treated patients, indicating the normalization of glucose and fatty acid metabolism with cytoreductive therapy. ntPV was also associated with altered B-vitamin metabolism, including decreased nicotinic acid adenine dinucleotide and increased nicotinamide ribotide levels. Cross-comparison analysis revealed overlapping pathway enrichment in glutamate metabolism, nicotinate and nicotinamide metabolism, and cysteine metabolism between both comparisons. Conclusions: This study demonstrates that PV and SP exhibit fundamentally distinct metabolic signatures, providing novel insights into disease pathogenesis and potential diagnostic biomarkers. The identification of oxidative stress signatures, disrupted energy metabolism, and altered B-vitamin cofactor pathways distinguishes PV from SP at the molecular level. Cytoreductive therapy significantly normalizes metabolic dysregulation, particularly glucose and nucleotide metabolism, validating current therapeutic approaches while revealing broader systemic treatment effects. The metabolic signatures identified, particularly the combination of deoxyuridine, thyrotropin-releasing hormone, and oxidative stress metabolites, may serve as complementary diagnostic tools to traditional morphological and molecular approaches. These findings advance our understanding of myeloproliferative neoplasm pathophysiology and provide a foundation for developing metabolically targeted therapeutic strategies and precision medicine approaches in PV management.
- Open Access
- 6 June 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (6) , 376
Metabolomic Profiling and Bioanalysis of Chronic Myeloid Leukemia: Identifying Biomarkers for Treatment Response and Disease Monitoring
Background: Including Chronic Myeloid Leukemia (CML) patients with deep molecular responses (MR4.5) and those with suboptimal responses provides valuable insights into treatment-associated metabolic changes. This study aimed to characterize the metabolomic alterations associated with CML and identify potential biomarkers for treatment response, particularly in patients achieving a deeper molecular response versus those with poorer responses. Methods: Plasma samples were collected from 51 chronic-phase CML patients and 24 healthy controls. CML patients were classified into two groups based on molecular responses: T1 (BCR-ABL1 IS ≤ 0.0032%) and T2 (BCR-ABL1 IS > 0.0032%, 1.5 included glutamate, hypoxanthine, and D-galactonic acid. In the T2 group, significant increases in malate and 5-aminoimidazole-4-carboxamide ribonucleotide were observed, reflecting disruptions in purine metabolism, the tricarboxylic acid cycle, and amino acid metabolism. The pathway enrichment analysis highlighted significant alterations in CML energy metabolism, nucleotide synthesis, and amino acid biosynthesis. Conclusions: CML patients exhibit pronounced metabolic changes, particularly in energy and nucleotide metabolism, which are linked to treatment response. These findings provide novel insights into CML biology and suggest potential biomarkers for monitoring treatment efficacy and predicting outcomes and therapeutic targets for improving treatment outcomes and overcoming tyrosine kinase inhibitor resistance.
- 6 June 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (6) , 376
Open AccessMetabolomic Profiling and Bioanalysis of Chronic Myeloid Leukemia: Identifying Biomarkers for Treatment Response and Disease Monitoring
Background: Including Chronic Myeloid Leukemia (CML) patients with deep molecular responses (MR4.5) and those with suboptimal responses provides valuable insights into treatment-associated metabolic changes. This study aimed to characterize the metabolomic alterations associated with CML and identify potential biomarkers for treatment response, particularly in patients achieving a deeper molecular response versus those with poorer responses. Methods: Plasma samples were collected from 51 chronic-phase CML patients and 24 healthy controls. CML patients were classified into two groups based on molecular responses: T1 (BCR-ABL1 IS ≤ 0.0032%) and T2 (BCR-ABL1 IS > 0.0032%, 1.5 included glutamate, hypoxanthine, and D-galactonic acid. In the T2 group, significant increases in malate and 5-aminoimidazole-4-carboxamide ribonucleotide were observed, reflecting disruptions in purine metabolism, the tricarboxylic acid cycle, and amino acid metabolism. The pathway enrichment analysis highlighted significant alterations in CML energy metabolism, nucleotide synthesis, and amino acid biosynthesis. Conclusions: CML patients exhibit pronounced metabolic changes, particularly in energy and nucleotide metabolism, which are linked to treatment response. These findings provide novel insights into CML biology and suggest potential biomarkers for monitoring treatment efficacy and predicting outcomes and therapeutic targets for improving treatment outcomes and overcoming tyrosine kinase inhibitor resistance.
- 28 August 2024
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 28 (9) , 1-13
Prevention of secondary caries using fluoride-loaded chitosan nanoparticle-modified glass-ionomer cement
Objective To study the effect of incorporating chitosan and fluoride-loaded chitosan nanoparticles into a glass-ionomer cement (GIC) to prevent secondary caries. Materials and methods A standard cervical cavity (mesio-distal width 6 mm, cervico-occlusal width 2 mm, and depth 2 mm) was prepared on 30 molars for the following restoration groups: group 1, conventional GIC restoration; group 2, chitosan (10%) modified GIC restoration; group 3, fluoride loaded chitosan nanoparticles (10%) modified GIC restoration. The restored teeth were subjected to 1,500 thermal cycles before undergoing a multi-species cariogenic biofilm challenge. The restored teeth were examined by micro-computed tomography (micro-CT), scanning electron microscopy with energy dispersive X-ray spectroscopy (SEM/EDX). Data were analyzed by the one-way ANOVA, Tukey HDS, Kruskal Wallis, and Dunn’s test. Results Micro-CT determined outer lesion depths for groups 1–3 were: 614 ± 20 μm, 589 ± 17 μm, and 560 ± 19 μm respectively. Both modifications with chitosan and fluoride-loaded chitosan nanoparticles significantly affected outer lesion depth (p < 0.05). The modification with fluoride-loaded chitosan nanoparticles statistically significantly decreased the outer lesion depth compared to all other groups (p < 0.05). SEM/EDX showed an increase of calcium, phosphorus, and fluoride at the root dentine adjacent to the restoration in groups 2 and 3 (modified GIC). This increase was statistically significantly higher in the group modified with fluorine-loaded nano chitosan particles compared to the other groups (p < 0.05). Conclusion Incorporation of 10% chitosan and 10% fluoride-loaded chitosan nanoparticles into GIC restorative material can prevent secondary root caries development. 10% fluoride-loaded chitosan nanoparticles were more effective. Clinical significance Glass ionomer cement modified with fluoride-loaded chitosan nanoparticles may be a promising restorative material in pediatric and preventive dentistry due to their controlled release properties.
- 28 August 2024
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 28 (9) , 1-13
Prevention of secondary caries using fluoride-loaded chitosan nanoparticle-modified glass-ionomer cement
Objective To study the effect of incorporating chitosan and fluoride-loaded chitosan nanoparticles into a glass-ionomer cement (GIC) to prevent secondary caries. Materials and methods A standard cervical cavity (mesio-distal width 6 mm, cervico-occlusal width 2 mm, and depth 2 mm) was prepared on 30 molars for the following restoration groups: group 1, conventional GIC restoration; group 2, chitosan (10%) modified GIC restoration; group 3, fluoride loaded chitosan nanoparticles (10%) modified GIC restoration. The restored teeth were subjected to 1,500 thermal cycles before undergoing a multi-species cariogenic biofilm challenge. The restored teeth were examined by micro-computed tomography (micro-CT), scanning electron microscopy with energy dispersive X-ray spectroscopy (SEM/EDX). Data were analyzed by the one-way ANOVA, Tukey HDS, Kruskal Wallis, and Dunn’s test. Results Micro-CT determined outer lesion depths for groups 1–3 were: 614 ± 20 μm, 589 ± 17 μm, and 560 ± 19 μm respectively. Both modifications with chitosan and fluoride-loaded chitosan nanoparticles significantly affected outer lesion depth (p < 0.05). The modification with fluoride-loaded chitosan nanoparticles statistically significantly decreased the outer lesion depth compared to all other groups (p < 0.05). SEM/EDX showed an increase of calcium, phosphorus, and fluoride at the root dentine adjacent to the restoration in groups 2 and 3 (modified GIC). This increase was statistically significantly higher in the group modified with fluorine-loaded nano chitosan particles compared to the other groups (p < 0.05). Conclusion Incorporation of 10% chitosan and 10% fluoride-loaded chitosan nanoparticles into GIC restorative material can prevent secondary root caries development. 10% fluoride-loaded chitosan nanoparticles were more effective. Clinical significance Glass ionomer cement modified with fluoride-loaded chitosan nanoparticles may be a promising restorative material in pediatric and preventive dentistry due to their controlled release properties.
- Open Access
- 29 January 2021
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 3 (1) , 6-12
Assessment of The Performances of Hepatitis C Virus Viral Markers, Age-Platelet Index and Aspartate aminotransferase to Alanine Aminotransferase Ratio Scores, in Predicting Liver Histopathology
Introduction This study aimed to reveal the utility of age-platelet (AP) index and aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio (AAR), which are non-invasive markers, in patients with chronic Hepatitis C virus (HCV) infection in prediction of fibrosis and evaluate whether viral markers could be used for that purpose or not. Methods A total of treatment-naïve 49 patients with chronic HCV who underwent liver biopsy were included in this retrospective study. Anti-HCV S/CO and HCV-RNA viral load (copy/ml) values measured simultaneously with biopsy were determined. AP index and AAR score were calculated and compared. Results Staging of liver biopsy samples of 49 HCV patients was assessed. Comparable diagnostic accuracies of AP index and AAR in prediction of significant fibrosis (F≥2) were showed with ROC curve analysis. The areas under the ROC (AUROCs) were 0.713 and 0.506 respectively. Diagnostic accuracy of API in prediction of significant fibrosis was superior to that of AAR (p=0.03). AUROC of HCV-RNA viral load in prediction of F≥2 was 0.531. Anti-HCV S/CO value (AUROC=0.464) was not found as a suitable marker in prediction of fibrosis. Conclusions AP index, AAR score and HCV viral load among non-invasive markers assessed in this study were useful in predicting significant fibrosis. Especially API was the most useful test in predicting significant fibrosis. AP index can be preferred in patients with near normal ALT values.
- 29 January 2021
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 3 (1) , 6-12
Open AccessAssessment of The Performances of Hepatitis C Virus Viral Markers, Age-Platelet Index and Aspartate aminotransferase to Alanine Aminotransferase Ratio Scores, in Predicting Liver Histopathology
Introduction This study aimed to reveal the utility of age-platelet (AP) index and aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio (AAR), which are non-invasive markers, in patients with chronic Hepatitis C virus (HCV) infection in prediction of fibrosis and evaluate whether viral markers could be used for that purpose or not. Methods A total of treatment-naïve 49 patients with chronic HCV who underwent liver biopsy were included in this retrospective study. Anti-HCV S/CO and HCV-RNA viral load (copy/ml) values measured simultaneously with biopsy were determined. AP index and AAR score were calculated and compared. Results Staging of liver biopsy samples of 49 HCV patients was assessed. Comparable diagnostic accuracies of AP index and AAR in prediction of significant fibrosis (F≥2) were showed with ROC curve analysis. The areas under the ROC (AUROCs) were 0.713 and 0.506 respectively. Diagnostic accuracy of API in prediction of significant fibrosis was superior to that of AAR (p=0.03). AUROC of HCV-RNA viral load in prediction of F≥2 was 0.531. Anti-HCV S/CO value (AUROC=0.464) was not found as a suitable marker in prediction of fibrosis. Conclusions AP index, AAR score and HCV viral load among non-invasive markers assessed in this study were useful in predicting significant fibrosis. Especially API was the most useful test in predicting significant fibrosis. AP index can be preferred in patients with near normal ALT values.
- Open Access
- 17 January 2021
- Published by JSC National Scientific Medical Research Center in Journal of Clinical Medicine of Kazakhstan
- Vol. 18 (1) , 23-27
Three-year prevalence of measles antibody seropositivity at a tertiary care hospital in Turkey
Objective: Measles virus is an unsegmented, single-stranded and negative-polarized RNA virus belonging to Morbillivirus genus in Paramyxoviridae family in the order of Mononegavirales. This study aimed to evaluate measles antibody seropositivity proportions in different age groups from different geographical regions within three years. Material and methods: This retrospective study, IgM and IgG antibodies specific to measles were detected in serum samples with enzyme immunoassay method. Measles IgG antibody seroprevalence was calculated by correlating all data with demographic variables. Results: Median age of patients included in the study was 27 years and while 352 (44.4%) were male. Seropositivity rate of measles IgG antibody was 87.1%. Seropositivity in the age group of 0-18 was 77.7% (p = 0.002). IgG seropositivity rates were 82.8%, 88.8% and 90.7% between 2017 and 2019 respectively (p = 0.05). Seropositivity rate of IgM antibody in all cases was 11.1% and the highest rate was detected in the age group of 0-18 (13.5%) (p = 0.09). IgM antibody seropositivity rate was determined most in the winter months (23.8%) (p < 0.001). While measles IgM positivities were 10.6% and 21.1% in Turkish and foreign patients respectively IgG positivities were 86.9% and 92.3% (p = 0.32, p = 1.00 respectively). Measles IgG seropositivity was the highest in patients living in Aegean region (96.8%). Conclusions: In conclusion, measles IgG seropositivity was 87.1% in this study. This rate was lower in pediatric age group. Increasing regional seroprevalence studies may help enhancement efforts on vaccination program to reach and sustain high population immunity.
- 17 January 2021
- Published by JSC National Scientific Medical Research Center in Journal of Clinical Medicine of Kazakhstan
- Vol. 18 (1) , 23-27
Open AccessThree-year prevalence of measles antibody seropositivity at a tertiary care hospital in Turkey
Objective: Measles virus is an unsegmented, single-stranded and negative-polarized RNA virus belonging to Morbillivirus genus in Paramyxoviridae family in the order of Mononegavirales. This study aimed to evaluate measles antibody seropositivity proportions in different age groups from different geographical regions within three years. Material and methods: This retrospective study, IgM and IgG antibodies specific to measles were detected in serum samples with enzyme immunoassay method. Measles IgG antibody seroprevalence was calculated by correlating all data with demographic variables. Results: Median age of patients included in the study was 27 years and while 352 (44.4%) were male. Seropositivity rate of measles IgG antibody was 87.1%. Seropositivity in the age group of 0-18 was 77.7% (p = 0.002). IgG seropositivity rates were 82.8%, 88.8% and 90.7% between 2017 and 2019 respectively (p = 0.05). Seropositivity rate of IgM antibody in all cases was 11.1% and the highest rate was detected in the age group of 0-18 (13.5%) (p = 0.09). IgM antibody seropositivity rate was determined most in the winter months (23.8%) (p < 0.001). While measles IgM positivities were 10.6% and 21.1% in Turkish and foreign patients respectively IgG positivities were 86.9% and 92.3% (p = 0.32, p = 1.00 respectively). Measles IgG seropositivity was the highest in patients living in Aegean region (96.8%). Conclusions: In conclusion, measles IgG seropositivity was 87.1% in this study. This rate was lower in pediatric age group. Increasing regional seroprevalence studies may help enhancement efforts on vaccination program to reach and sustain high population immunity.
- Open Access
- 29 November 2020
- Published by Politeknik Kementerian Kesehatan Banjarmasin in Medical Laboratory Technology Journal
- Vol. 6 (2) , 163-171
Evaluation of Toxoplasma gondii IgM and IgG Seropositivities in Serum Samples Sent from Pediatric and Adult Hematology/Oncology Outpatient Clinics
Toxoplasmosis, despite its mild course in immunocompetent individuals, it may have a more severe course in immunosuppressed patients such as hematology and oncology patients. This study aimed to contribute to the importance of that issue by evaluating the seropositivity rates of Toxoplasma gondii (T. gondii) in Hematology and Oncology patients and sharing the data obtained. Serum samples sent from pediatric and adult Hematology/Oncology outpatient clinic to the Microbiology Laboratory between January 2017 and August 2019 were analysed using Architect Toxo IgG and IgM Reagent Kit with chemiluminescent microparticular enzyme immunoassay method on Architect system. A total of 673 patient samples belonging to 131 pediatric patients and 542 adult patients were analysed in the study. Median age of the study group was 29 (range: 0 - 83) and 53.5% of them were male. While T. gondii IgM positivity was 8% IgG positivity was 28.7%. T. gondii IgG seropositivities in male and female patients were 27.2% and 30.4% respectively (p = 0.44). T. gondii IgM seropositivities in pediatric and adult patients were 6.9% and 8.3% respectively and IgG seropositivities were 24.4% and 29.7% (p = 0.78 and p = 0.46 respectively). T. gondii IgM positivity was found as 8% and IgG positivity as 28.7% in the study group. In conclusion, data obtained from the study were in compliance with both domestic and foreign data and the highest rate of IgM and IgG seropositivity was found in patients with lymphoma.
- 29 November 2020
- Published by Politeknik Kementerian Kesehatan Banjarmasin in Medical Laboratory Technology Journal
- Vol. 6 (2) , 163-171
Open AccessEvaluation of Toxoplasma gondii IgM and IgG Seropositivities in Serum Samples Sent from Pediatric and Adult Hematology/Oncology Outpatient Clinics
Toxoplasmosis, despite its mild course in immunocompetent individuals, it may have a more severe course in immunosuppressed patients such as hematology and oncology patients. This study aimed to contribute to the importance of that issue by evaluating the seropositivity rates of Toxoplasma gondii (T. gondii) in Hematology and Oncology patients and sharing the data obtained. Serum samples sent from pediatric and adult Hematology/Oncology outpatient clinic to the Microbiology Laboratory between January 2017 and August 2019 were analysed using Architect Toxo IgG and IgM Reagent Kit with chemiluminescent microparticular enzyme immunoassay method on Architect system. A total of 673 patient samples belonging to 131 pediatric patients and 542 adult patients were analysed in the study. Median age of the study group was 29 (range: 0 - 83) and 53.5% of them were male. While T. gondii IgM positivity was 8% IgG positivity was 28.7%. T. gondii IgG seropositivities in male and female patients were 27.2% and 30.4% respectively (p = 0.44). T. gondii IgM seropositivities in pediatric and adult patients were 6.9% and 8.3% respectively and IgG seropositivities were 24.4% and 29.7% (p = 0.78 and p = 0.46 respectively). T. gondii IgM positivity was found as 8% and IgG positivity as 28.7% in the study group. In conclusion, data obtained from the study were in compliance with both domestic and foreign data and the highest rate of IgM and IgG seropositivity was found in patients with lymphoma.
- Open Access
- 1 September 2019
- Published by Modestum Ltd in Ortadoğu Tıp Dergisi
- Vol. 11 (3) , 333-341
Royal jelly: a natural therapeutic?
- 1 September 2019
- Published by Modestum Ltd in Ortadoğu Tıp Dergisi
- Vol. 11 (3) , 333-341
Open AccessRoyal jelly: a natural therapeutic?
- 29 April 2019
- Published by Turkish Journal of Academic Gastroenterology in Akademik Gastroenteroloji Dergisi
- Vol. 19 (1) , 25-30
The Relationship Between Histopathological Stages of Liver Fibrosis and Albumin–Bilirubin Score in Chronic Hepatitis C Infection
Giriş ve Amaç: Karaciğer fibrozunu değerlendirmek için birçok invaziv olmayan biyokimyasal indeksler geliştirilmiştir. Bu çalışmada allbümin-bilirübin skorunun kronik hepatit C virüs enfeksiyonunda gelişen karaciğer fibrozunun tahmininde karaciğer biyopsisine alternatif bir tanı yöntemi olup olamayacağının değerlendirilmesi ve diğer biyokimyasal belirteçler olan fibrozis-4 ve aspartat aminotransferaz/trombosit oran indeksi ile karşılaştırılması amaçlanmıştır. Gereç ve Yöntem: Yaş aralığı 20 ile 82 arasında değişen, karaciğer biyopsisi yapılmış, 27’si erkek ve 11’i kadın toplam 38 kronik hepatit C virüs enfeksiyonlu hasta değerlendirildi. Albümin-bilirübin, fibrozis-4 ve aspartat aminotransferaz/trombosit oran indeks skorları hesaplandı. Albümin-bilirübin skorunun fibrozis evre >2 ve >4’ü ayırt etme yeteneği ROC analizi ile değerlendirildi ve fibrozis-4 ve aspartat aminotransferaz/trombosit oran indeks skoru ile karşılaştırıldı. Bulgular: Albümin-bilirübin skorunun fibrozis evre >2 ve fibrozis evre ≥4 tanısı için ROC eğrisi altında kalan alan sırasıyla 0.767 (95% Cl: 0.564-0.969) ve 0.956 (95% Cl: 0.889-1.000) bulunurken, fibrozis-4 için 0.863 (95% Cl: 0.714-1.000) ve 0.926 (95% Cl: 0.833-1.000), aspartat aminotransferaz/ trombosit oran indeks skoru için 0.667 (95% Cl: 0.450-0.884) ve 0.640 (95% Cl: 0.378-0.901) idi. Sonuç: Bulgulara göre albümin-bilirübin skorunun fibrozis evre >2 ve ileri karaciğer fibrozunu (fibrozis evre >4) tahmin edebileceği değerlendirilmiştir. Albümin-bilirübin skorunun fibrozis tahminindeki performansı, aspartat aminotransferaz/trombosit oran indeks skoru ve fibrozis-4 ile karşılaştırıldığında sonuçların benzer olduğu ancak fibrozis evre >2 tahmininde fibrozis-4’ün, fibrozis evre ≥4’de ise aspartat aminotransferaz/ trombosit oran indeks skorunun daha güvenilir sonuç verdiği değerlendirilmiştir.
- 29 April 2019
- Published by Turkish Journal of Academic Gastroenterology in Akademik Gastroenteroloji Dergisi
- Vol. 19 (1) , 25-30
The Relationship Between Histopathological Stages of Liver Fibrosis and Albumin–Bilirubin Score in Chronic Hepatitis C Infection
Giriş ve Amaç: Karaciğer fibrozunu değerlendirmek için birçok invaziv olmayan biyokimyasal indeksler geliştirilmiştir. Bu çalışmada allbümin-bilirübin skorunun kronik hepatit C virüs enfeksiyonunda gelişen karaciğer fibrozunun tahmininde karaciğer biyopsisine alternatif bir tanı yöntemi olup olamayacağının değerlendirilmesi ve diğer biyokimyasal belirteçler olan fibrozis-4 ve aspartat aminotransferaz/trombosit oran indeksi ile karşılaştırılması amaçlanmıştır. Gereç ve Yöntem: Yaş aralığı 20 ile 82 arasında değişen, karaciğer biyopsisi yapılmış, 27’si erkek ve 11’i kadın toplam 38 kronik hepatit C virüs enfeksiyonlu hasta değerlendirildi. Albümin-bilirübin, fibrozis-4 ve aspartat aminotransferaz/trombosit oran indeks skorları hesaplandı. Albümin-bilirübin skorunun fibrozis evre >2 ve >4’ü ayırt etme yeteneği ROC analizi ile değerlendirildi ve fibrozis-4 ve aspartat aminotransferaz/trombosit oran indeks skoru ile karşılaştırıldı. Bulgular: Albümin-bilirübin skorunun fibrozis evre >2 ve fibrozis evre ≥4 tanısı için ROC eğrisi altında kalan alan sırasıyla 0.767 (95% Cl: 0.564-0.969) ve 0.956 (95% Cl: 0.889-1.000) bulunurken, fibrozis-4 için 0.863 (95% Cl: 0.714-1.000) ve 0.926 (95% Cl: 0.833-1.000), aspartat aminotransferaz/ trombosit oran indeks skoru için 0.667 (95% Cl: 0.450-0.884) ve 0.640 (95% Cl: 0.378-0.901) idi. Sonuç: Bulgulara göre albümin-bilirübin skorunun fibrozis evre >2 ve ileri karaciğer fibrozunu (fibrozis evre >4) tahmin edebileceği değerlendirilmiştir. Albümin-bilirübin skorunun fibrozis tahminindeki performansı, aspartat aminotransferaz/trombosit oran indeks skoru ve fibrozis-4 ile karşılaştırıldığında sonuçların benzer olduğu ancak fibrozis evre >2 tahmininde fibrozis-4’ün, fibrozis evre ≥4’de ise aspartat aminotransferaz/ trombosit oran indeks skorunun daha güvenilir sonuç verdiği değerlendirilmiştir.